Effects of angiotensin receptor blockade on atrial electrical remodelling and the 'second factor' in a goat burst-paced model of atrial fibrillation

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 11, Issue 4, 2010, Pages 222-233

  Hall, Mark C S ^a   Kirubakaran, Senthil ^b   Choudhury, Rasheda ^c   Abidin, Nik ^b   Peters, Nicholas S ^c   Garratt, Clifford J ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^b Manchester Heart Centre   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

angiotensin; animal model; atrial fibrillation; atrial remodelling; candesartan; electrophysiology

Indexed keywords

ANGIOTENSIN RECEPTOR; CANDESARTAN HEXETIL; PLACEBO;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROSTIMULATION; FEMALE; GOAT; HEART ATRIUM FIBRILLATION; NONHUMAN; RECEPTOR BLOCKING; REFRACTORY PERIOD; SINUS RHYTHM;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; GOATS; HEART ATRIA; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TIME FACTORS; VENTRICULAR FUNCTION;

EID: 78049493075     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320310369604     Document Type: Article

References (23)

1. Feinberg WM, Blackshear JL, Laupacis A., Kronmal R., and Hart RG Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Int Med 1995 ; 155: 469-73.
2. Stewart S., McMurray JJ Atrial fibrillation and the aging population- an emerging epidemic. Eur Heart J 2002 ; 23: 617. 3. Kannel WB, Wolf PA, and Benjamin EJ Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am J Cardiol 1998 ; 82: 2N - 9N.
3. Wijffels MC, Kirchhof CJ, Dorland R., and Allessie MA Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 ; 92: 1954-8.
4. Allessie M., Ausma J., Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002 ; 54: 230-46.
5. Todd DM, Fynn SP, Walden AP, Hobbs WJ, Arya S., and Garratt CJ Repetitive 4-week periods of atrial electrical remodeling promote stability of atrial fibrillation: time course of a second factor involved in the self-perpetuation of atrial fibrillation. Circulation 2004 ; 109: 1434-9.
6. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002 ; 106: 331-6.
7. Berk BC Angiotensin II receptors and angiotensin IIstimulated signal transduction. Heart Fail Rev 1998 ; 3: 87-99.
8. Brundel BJ, Ausma J., van Gelder IC, et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 2002 ; 54: 380-9.
9. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., and Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003 ; 41: 2197-204.
10. Schoonderwoerd BA, Ausma J., Crijns HJ, Van Veldhuisen DJ, Blaauw EH, and Van Gelder IC Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol 2004 ; 15: 1167-74.
11. Ausma J., Wijffels M., Thone F., Wouters L., Allessie M., and Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997 ; 96: 3157-63.
12. Thompson PJ, Kemp MW, McAllister WA, Al Habet SM, and Turner-Warwick ME Angiotensin-converting enzyme. Investigation of diurnal variation, the effect of a large dose of prednisolone, and prednisolone pharmacokinetics in patients with sarcoidosis. Am Rev Respir Dis 1986 ; 134: 1075-7.
13. Kerber RE, Wilson RL, and Marcus ML An animal model for experimental echocardiographic studies. J Clin Ultrasound 1976 ; 4: 343-7.
14. Sanmillan, Cabrera A, and Santos-Gallego G. Enalapril prevents electrical and structural remodeling in a canine model of atrial fibrillation: molecular mechanisms. Heart Rhythm 2005 ; 2: S70.
15. Shi Y., Li D., Tardif JC, and Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002 ; 54: 456-61.
16. Shinagawa K., Mitamura H., Ogawa S., and Nattel S. Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002 ; 54: 438-46.
17. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., and Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000 ; 101: 2612-7.
18. Anné W., Willems R., Holemans P., et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007 ; 43: 148-58.
19. Pedersen OD, Bagger H., Kober L., and Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999 ; 100: 376-80.
20. Madrid AH, Marín IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004 ; 5: 114-20.
21. Vermes E., Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight into the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003 ; 107: 2926-31.
22. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. New Engl J Med 2009 ; 360: 1606-17.
23. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo MA, and Maseri A.: Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997 ; 96: 1180-4.